*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1990 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus.  Any research using this corpus or based   *x*
*x*    on it should acknowledge that fact, as well as the preliminary   *x*
*x*    nature of the corpus.                                            *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*



======================================

[ A/DT House/NNP subcommittee/NN ]
said/VBD in/IN 
[ a/DT letter/NN ]
to/TO 
[ the/DT Epilepsy/NNP Foundation/NNP ]
of/IN 
[ America/NNP ]
that/IN 
[ it/PRP ]
has/VBZ ``/`` 
[ no/DT confidence/NN ]
''/'' that/IN 
[ generic/JJ anti-epileptic/JJ drugs/NNS ]
are/VBP safe/JJ ./. 

======================================

[ The/DT subcommittee/NN ]
said/VBD 
[ its/PRP$ investigation/NN ]
``/`` leaves/VBZ 
[ us/PRP ]
with/IN 
[ no/DT confidence/NN ]
''/'' that/IN 
[ the/DT Food/NNP ]
and/CC 
[ Drug/NNP Administration/NNP ]
``/`` has/VBZ 
[ the/DT ability/NN ]
,/, or/CC that/IN 
[ a/DT significant/JJ portion/NN ]
of/IN 
[ the/DT generic/JJ drug/NN industry/NN ]
has/VBZ 
[ the/DT integrity/NN ]
,/, to/TO assure/VB that/IN 
[ the/DT manufacture/NN ]
of/IN extremely/RB 
[ sensitive/JJ medications/NNS ]
''/'' is/VBZ safe/JJ ./. 

======================================

[ Rep./NNP John/NNP Dingell/NNP ]
 (/( 
[ D./NNP ]
,/, 
[ Mich./NNP ]
 )/) ,/, 
[ chairman/NN ]
of/IN 
[ the/DT subcommittee/NN ]
,/, also/RB asked/VBD 
[ the/DT FDA/NNP ]
in/IN 
[ a/DT letter/NN ]
to/TO review/VB ``/`` 
[ all/DT drugs/NNS ]
used/VBN to/TO treat/VB 
[ epilepsy/NN ]
and/CC 
[ any/DT other/JJ narrow/JJ therapeutic/JJ range/NN medication/NN ]
''/'' made/VBN by/IN 
[ generic/JJ drug/NN companies/NNS ]

[ that/WDT ]
are/VBP considered/VBN equivalent/JJ to/TO brand/NN 
[ name/NN drugs/NNS ]
./. 

======================================

Specifically/RB ,/, 
[ the/DT Dingell/NNP subcommittee/NN ]
cited/VBD 
[ a/DT 1988/CD recall/NN ]
of/IN 
[ carbamazepine/NN ]
,/, 
[ an/DT anti-epileptic/JJ drug/NN ]
made/VBN by/IN 
[ Pharmaceutical/NNP Basics/NNP Inc./NNP ]
,/, 
[ Denver/NNP ]
,/, 
[ Colo./NNP ]
,/, 
[ a/DT unit/NN ]
of/IN 
[ Akzo/NNP N.V/NNP ]
./. 

[ The/DT subcommittee/NN ]
also/RB said/VBD 
[ it/PRP ]
has/VBZ ``/`` 
[ preliminary/JJ information/NN ]
''/'' that/IN 
[ two/CD other/JJ generic/JJ drug/NN makers/NNS ]
``/`` may/MD have/VB made/VBN 
[ misrepresentations/NNS ]
''/'' to/TO obtain/VB 
[ FDA/NNP clearance/NN ]
for/IN 
[ diazepam/NN ]
,/, 
[ the/DT generic/JJ version/NN ]
of/IN 
[ Valium/NNP ]
,/, also/RB used/VBN for/IN 
[ epilepsy/NN ]
./. 

======================================

[ Pharmaceutical/NNP Basics/NNP ]
said/VBD in/IN 
[ a/DT statement/NN ]
that/IN 
[ its/PRP$ recall/NN ]
of/IN 
[ carbamazepine/NN ]
was/VBD due/JJ to/TO 
[ problems/NNS ]
with/IN 
[ the/DT drug/NN ]
properly/RB dissolving/VBG ./. 

[ The/DT company/NN ]
said/VBD that/IN is/VBZ n't/RB ``/`` 
[ an/DT unusual/JJ problem/NN ]
for/IN 
[ this/DT particular/JJ drug/NN ]
regardless/RB of/IN 
[ the/DT manufacturer/NN ]
./. 

''/'' 
[ It/PRP ]
added/VBD that/IN 
[ it/PRP ]
has/VBZ increased/VBN 
[ controls/NNS ]
to/TO 
[ its/PRP$ manufacturing/NN process/NN ]
to/TO assure/VB 
[ the/DT safety/NN ]
and/CC 
[ efficacy/NN ]
of/IN 
[ the/DT product/NN ]
./. 

======================================

[ The/DT FDA/NNP ]
said/VBD 
[ it/PRP ]
is/VBZ in/IN 
[ the/DT process/NN ]
of/IN reviewing/VBG 
[ the/DT country/NN 's/POS top/JJ 30/CD selling/JJ drugs/NNS ]
,/, including/VBG 
[ some/DT anti-seizure/JJ medications/NNS ]
,/, and/CC that/IN 
[ it/PRP ]

[ has/VBZ n't/RB ]
turned/VBN up/RP 
[ any/DT serious/JJ problems/NNS ]
./. 

[ One/CD ]
of/IN 
[ the/DT most/RBS common/JJ problems/NNS ]
,/, 
[ an/DT agency/NN spokesman/NN ]
said/VBD ,/, is/VBZ that/IN 
[ drugs/NNS ]
do/VBP n't/RB dissolve/VB properly/RB ./. 

[ The/DT Dingell/NNP subcommittee/NN ]
contended/VBD 
[ carbamazepine/NN problems/NNS ]
were/VBD 
[ the/DT result/NN ]
of/IN 
[ the/DT firm/NN ]
switching/VBG ``/`` from/IN 
[ a/DT ]
more/RBR expensive/JJ to/TO 
[ a/DT cheaper/JJR raw/JJ material/NN supplier/NN ]
./. 

''/'' But/CC 
[ Pharmaceutical/NNP Basics/NNP ]
said/VBD 
[ any/DT implication/NN ]
``/`` that/IN 
[ our/PRP$ choice/NN ]
of/IN either/DT of/IN 
[ our/PRP$ suppliers/NNS ]
of/IN 
[ this/DT raw/JJ material/NN ]
was/VBD based/VBN on/IN 
[ cost/NN consideration/NN ]
rather/RB than/IN 
[ quality/NN ]
and/CC 
[ continuity/NN ]
of/IN 
[ supply/NN ]
is/VBZ wrong/JJ ./. 

''/'' 
======================================

[ Several/JJ people/NNS ]
had/VBD 
[ seizures/NNS ]
because/IN 
[ the/DT drug/NN ]
passed/VBD through/IN 
[ their/PRP$ bodies/NNS ]
without/IN dissolving/VBG ,/, and/CC at/IN 
[ least/JJS one/CD person/NN ]
died/VBD ,/, according/VBG to/TO 
[ the/DT FDA/NNP recall/NN report/NN ]
./. 

[ Hospital/NNP records/NNS ]
indicated/VBD that/IN 
[ the/DT tablets/NNS ]
were/VBD ``/`` 
[ sub-therapeutic/JJ ]
,/, ''/'' 
[ the/DT report/NN ]
said/VBD ./. 

======================================

However/RB ,/, 
[ Pharmaceutical/NNP Basics/NNP ]
contended/VBD ,/, ``/`` 
[ any/DT implication/NN ]
that/IN 
[ the/DT problems/NNS we/PRP ]
had/VBD with/IN 
[ this/DT drug.../: ]
caused/VBD 
[ mortality/NN ]
is/VBZ wrong/JJ ./. 

''/'' 
[ The/DT company/NN ]
said/VBD 
[ side/JJ effects/NNS ]
,/, including/VBG 
[ death/NN ]
,/, 
[ result/VBP ]
from/IN 
[ both/CC generic/JJ ]
and/CC 
[ brand/NN name/NN drugs/NNS ]
./. 
